New strategies in esophageal carcinoma: promises and problems.
作者信息
Xiong Zhaohui, He Jingxi, Chen Xiaoxin Luke
机构信息
Cancer Research Program, Julius L. Chambers Biomedical Biotechnology Research Institute, North Carolina Central University, Durham, NC 27707, USA.
Department of Thoracic Surgery, Ningxia Medical University General Hospital, Yinchuan 750004, China.
出版信息
J Thorac Dis. 2016 Nov;8(11):E1501-E1504. doi: 10.21037/jtd.2016.11.22.
Abstract
摘要
相似文献
1
New strategies in esophageal carcinoma: promises and problems.食管癌的新策略：前景与问题
J Thorac Dis. 2016 Nov;8(11):E1501-E1504. doi: 10.21037/jtd.2016.11.22.
2
[Interpretation of 2017 National Comprehensive Cancer Network (NCCN) guidelines for the diagnosis and treatment of esophageal squamous cell carcinoma through the new TNM staging of esophageal carcinoma (eighth edition) by the Union for International Cancer Control (UICC) and the American Cancer Commission (AJCC)].[通过国际癌症控制联盟（UICC）和美国癌症委员会（AJCC）食管癌新TNM分期（第八版）解读2017年美国国立综合癌症网络（NCCN）食管癌鳞状细胞癌诊疗指南]
Zhonghua Wei Chang Wai Ke Za Zhi. 2017 Oct 25;20(10):1122-1126.
3
Tissue engineering interventions for esophageal disorders--promises and challenges.组织工程学干预食管疾病的方法——前景与挑战。
Biotechnol Adv. 2012 Nov-Dec;30(6):1481-92. doi: 10.1016/j.biotechadv.2012.03.005. Epub 2012 Mar 28.
4
The prevalence and role of coping strategies in the nutritional intake of children born with esophageal atresia: a condition-specific approach.先天性食管闭锁患儿营养摄入中应对策略的流行情况和作用：一种特定于病情的方法。
Dis Esophagus. 2019 Jul 1;32(7). doi: 10.1093/dote/doz004.
5
[Discussion of the treatment of esophageal carcinoma,especially in the point of non-surgical treatments, from the viewpoint of medical oncology].
Gan To Kagaku Ryoho. 2007 Jun;34(6):831-5.
6
A method for establishing a patient-derived xenograft model to explore new therapeutic strategies for esophageal squamous cell carcinoma.一种建立患者来源异种移植模型以探索食管鳞状细胞癌新治疗策略的方法。
Oncol Rep. 2016 Feb;35(2):785-92. doi: 10.3892/or.2015.4459. Epub 2015 Nov 26.
7
Decision forest analysis of 61 single nucleotide polymorphisms in a case-control study of esophageal cancer; a novel method.
BMC Bioinformatics. 2005 Jul 15;6 Suppl 2(Suppl 2):S4. doi: 10.1186/1471-2105-6-S2-S4.
8
Synchronous occurrence of hereditary gastric adenocarcinoma, gastrointestinal stromal tumor, and esophageal small cell and squamous carcinoma in situ: an extremely rare case report.遗传性胃腺癌、胃肠道间质瘤、食管原位小细胞癌和鳞癌同时发生：一例极其罕见的病例报告。
BMC Cancer. 2017 Nov 7;17(1):720. doi: 10.1186/s12885-017-3736-0.
9
KIF-2C expression is correlated with poor prognosis of operable esophageal squamous cell carcinoma male patients.KIF-2C表达与可手术治疗的男性食管鳞状细胞癌患者的不良预后相关。
Oncotarget. 2016 Dec 6;7(49):80493-80507. doi: 10.18632/oncotarget.11492.
10
Chemoradiotherapy for esophageal squamous cell cancer.食管鳞状细胞癌的放化疗
Jpn J Clin Oncol. 2016 Sep;46(9):805-10. doi: 10.1093/jjco/hyw082. Epub 2016 Jul 5.
引用本文的文献
1
Dihydroartemisinin Inhibits the Proliferation of Esophageal Squamous Cell Carcinoma Partially by Targeting AKT1 and p70S6K.双氢青蒿素通过靶向AKT1和p70S6K部分抑制食管鳞状细胞癌的增殖。
Front Pharmacol. 2020 Nov 20;11:587470. doi: 10.3389/fphar.2020.587470. eCollection 2020.
2
Xiaoxin Chen: funding remains the greatest challenge to research due to constant improvement of technologies.陈小新：由于技术的不断进步，资金仍然是研究面临的最大挑战。
J Thorac Dis. 2018 May;10(5):E397-E399. doi: 10.21037/jtd.2018.05.124.
3
Establishment and genomic characterizations of patient-derived esophageal squamous cell carcinoma xenograft models using biopsies for treatment optimization.利用活检建立和基因组特征分析患者来源的食管鳞癌异种移植模型用于治疗优化。
J Transl Med. 2018 Jan 25;16(1):15. doi: 10.1186/s12967-018-1379-9.
本文引用的文献
1
Perspective: The precision-oncology illusion.观点：精准肿瘤学的错觉。
Nature. 2016 Sep 8;537(7619):S63. doi: 10.1038/537S63a.
2
Personalized and targeted therapy of esophageal squamous cell carcinoma: an update.食管鳞状细胞癌的个性化靶向治疗：最新进展
Ann N Y Acad Sci. 2016 Oct;1381(1):66-73. doi: 10.1111/nyas.13144. Epub 2016 Jul 11.
3
New Strategies in Esophageal Carcinoma: Translational Insights from Signaling Pathways and Immune Checkpoints.食管癌的新策略：信号通路和免疫检查点的转化见解。
Clin Cancer Res. 2016 Sep 1;22(17):4283-90. doi: 10.1158/1078-0432.CCR-16-0292. Epub 2016 Jul 1.
4
Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs.美国食品药品监督管理局批准肿瘤药物时所使用的替代终点的验证强度。
Mayo Clin Proc. 2016 May 10. doi: 10.1016/j.mayocp.2016.02.012.
5
Evidence Showing That Tumors Can Grow Without Angiogenesis and Can Switch Between Angiogenic and Nonangiogenic Phenotypes.有证据表明肿瘤可在无血管生成的情况下生长，并能在血管生成和非血管生成表型之间转换。
J Natl Cancer Inst. 2016 Apr 8;108(8). doi: 10.1093/jnci/djw032. Print 2016 Aug.
6
The Conundrum of Genetic "Drivers" in Benign Conditions.良性疾病中基因“驱动因素”的难题
J Natl Cancer Inst. 2016 Apr 7;108(8). doi: 10.1093/jnci/djw036. Print 2016 Aug.
7
Emerging immunotherapy for the treatment of esophageal cancer.用于治疗食管癌的新兴免疫疗法。
Expert Opin Investig Drugs. 2016 Jun;25(6):667-77. doi: 10.1517/13543784.2016.1163336. Epub 2016 Mar 24.
8
Targeted therapy in esophageal cancer.食管癌的靶向治疗
Expert Rev Gastroenterol Hepatol. 2016;10(5):595-604. doi: 10.1586/17474124.2016.1140036. Epub 2016 Feb 19.
9
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.肿瘤细胞可以沿着不同的进化路径对表皮生长因子受体抑制产生抗性。
Nat Med. 2016 Mar;22(3):262-9. doi: 10.1038/nm.4040. Epub 2016 Feb 1.
10
Role of Reactive Oxygen Species in the Abrogation of Oxaliplatin Activity by Cetuximab in Colorectal Cancer.活性氧在西妥昔单抗消除奥沙利铂对结直肠癌的活性中的作用
J Natl Cancer Inst. 2015 Dec 30;108(6):djv394. doi: 10.1093/jnci/djv394. Print 2016 Jun.
Zotero 插件